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KEY POINTS
 Mucosal healing is an important end point in clinical trials.
 Mucosal healing predicts the following:
 Less corticosteroid use
 Lower hospitalization rates
 Increased sustained clinical remission
 Lower colectomy and bowel resection rates
 Mucosal healing decreases the risk of colorectal cancer in ulcerative colitis (UC).
 Mucosal healing should be recognized by clinicians and health care providers as a goal for
inflammatory bowel disease (IBD) therapy.INTRODUCTION
UC and Crohn’s disease are characterized by the presence of gut inflammation
accompanied by areas of ulceration (Fig. 1). Mucosal healing is becoming increasingly
important in the clinical management of UC and Crohn’s disease, as well as being
used as an end point in clinical trials. Achieving mucosal healing has unequivocally
been associated with better outcomes, and for these reasons, it has become an
important treatment goal. There are, however, multiple methods to score endoscopic
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Fig. 1. Assessment of mucosal healing using the Ulcerative Colitis Endoscopic Index of
Severity (UCEIS) with descriptors of vascular pattern (V), bleeding (B), and erosions/ulcers
(E). (A) UCEIS 0 (V0 B0 E0), (B) UCEIS 5 (V2 B1 E0), and (C) UCEIS 8 (V2 B3 E3).
Walsh et al368those used most frequently or that have been validated: the Mayo endoscopic score
and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) for UC and the
Crohn’s Disease Endoscopic Index of Severity (CDEIS), the Simple Endoscopic Score
for Crohn’s Disease (SES-CD), and the Rutgeerts Postoperative Endoscopic Index for
Crohn’s disease. Because indices are complex and potentially confusing, the article
follows a standard approach describing the indices in this order.
DEFINITION OF MUCOSAL HEALING
Mucosal healing in the context of IBD refers to the endoscopic assessment of disease
activity. Simply stated, mucosal healing should imply the absence of ulceration and
erosions. Nevertheless, there is currently no validated definition of mucosal healing
in IBD.1–3
Ulcerative Colitis
In patients with UC, mucosal healing may represent the ultimate therapeutic goal,
because the disease is limited to the mucosa. The pattern of inflammation in UC is
associated with several mucosal changes, initially vascular congestion, erythema,
and granularity. As inflammation becomes more severe, friability (bleeding to light
touch), spontaneous bleeding, and erosions and ulcers develop. An International Or-
ganization of Inflammatory Bowel Disease (IOIBD) task force defined mucosal healing
in UC as the absence of friability, blood, erosions, and ulcers in all visualized segments
of the colonic mucosa.2 However, some studies allow erythema and friability in the
definition of mucosal healing.4 Many different endoscopic indices for UC have been
used in clinical trials, although none have been fully validated in prospective studies;
this creates problems when comparing trials.5
Crohn’s Disease
In contrast to UC, mucosal healing in Crohn’s disease might reasonably be considered
aminimum (rather than the ultimate) therapeutic goal, because the disease is transmu-
ral. Even this therapeutic goal, however, is not routine clinical practice in most centers.
The pattern of inflammation in Crohn’s disease is characterized by several mucosal
features that include patchy erythema, nodularity, aphthoid, and then deeper, serpig-
inous ulceration, strictures, and, in severe cases, penetrating ulcers. The complete
resolution of all visible ulcers is a simple definition of mucosal healing for clinical prac-
tice, and this is what has been suggested by IOIBD task force.6 Nevertheless, this
binomial definition (presence or absence of ulcers) is currently unvalidated, is difficult
to achieve, and is rather crude for use in therapeutic trials because it does not allow
quantification of improvement of mucosal inflammation.7 The largest trials that have
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nition of absence of ulcers rather than the prespecified cut-off values on the CDEIS or
SES-CD. Studies have yet to determine the minimum degree of endoscopic improve-
ment associated with improved clinical outcomes.
BENEFITS OF MUCOSAL HEALING
Mucosal healing in IBD has been associated with the following:
 Decreased need for corticosteroids8
 Decreased hospitalization rates9–11
 Sustained clinical remission11,12
 Decreased colectomy and bowel resection5,8,9,11,12
 Decreased risk of colorectal cancer13
Multivariate analysis of data from a case-controlled study of patients with long-
standing, extensive UC showed that those with endoscopically normal mucosa at sur-
veillance colonoscopy had the same 5-year cancer risk as the general population.13
The presence of persisting histologic inflammation was, however, a determinant of
risk for colorectal cancer.14 In the same surveillance population, evidence of postin-
flammatory polyps or strictures was associated with a significantly increased colo-
rectal cancer risk. For Crohn’s disease, there has been no demonstrable reduction
in colorectal cancer in those with mucosal healing.
Before monoclonal antibodies against tumor necrosis factor (anti-TNF) were intro-
duced for Crohn’s disease, a symptom-oriented management approach was com-
mon. This approach was largely used because of the failure to demonstrate a
correlation between endoscopic remission (mucosal healing) and decrease in relapse
rates in patients treated with steroids compared with clinical remission (symptom con-
trol). Steroids, however, do not heal the ileal or colonic mucosa. In contrast, both
azathioprine and anti-TNF therapy have now been shown to achieve and thenmaintain
mucosal healing, thereby influencing the course of Crohn’s disease.8,10
For these reasons, mucosal healing has emerged since 2012 as an important ther-
apeutic goal for both UC and Crohn’s disease. Moreover, because trials in IBD have
traditionally had a high placebo response rate, there is a move to include mucosal
healing as an end point in trials to drive down placebo rates.15,16 For most patients,
mucosal healing is only maintained with continued therapy. Current treatments do
not cure the disease, and therefore, cessation of therapy almost invariably leads to
disease recurrence.17 If mucosal healing influences the subsequent course of disease,
logic suggests that its presence should be confirmed or therapy augmented if it has
not been achieved. For these reasons, endoscopic assessment is increasingly used
in clinical practice to guide decision making in the management of IBD, but augment-
ing treatment in the absence of symptoms just because endoscopic lesions are pre-
sent remains a challenge to many clinicians. On the other hand, most are persuaded
that mucosal healing is an appropriate therapeutic goal when starting, stepping up,
switching, or stopping expensive biologic therapy.
LIMITATIONS OF MUCOSAL HEALING
Although colonoscopy is considered to be a low-risk invasive procedure, it still carries
a risk of perforation, bleeding, or sedation. Furthermore, colonoscopy is an investment
of time and resources both for the patient and the community.
Even when using validated indices such as the UCEIS and CDEIS, further research
is needed to determine what degree of improvement, measured by endoscopy, is
Walsh et al370clinically meaningful. In addition, although disease may seem inactive at endoscopy,
microscopic disease activity may persist. Persistent histologic activity is associated
with a shorter time to relapse in UC,18,19 so endoscopic mucosal healing alone may
be an insufficient therapeutic goal.20 Surrogate, noninvasive markers of mucosal heal-
ing are therefore needed, but biomarkers such as fecal calprotectin have yet to
demonstrate sufficient specificity for mucosal healing to replace endoscopic
assessment.17METHODS TO SCORE DISEASE ACTIVITY
Ulcerative Colitis
Truelove and Witts21 were the first to comment on mucosal appearance as a measure
of disease activity, using rigid sigmoidoscopy in the first placebo-controlled trial of
cortisone for UC in 1955. Since 1956, it has been recognized that endoscopic and his-
tologic microscopic changes can persist despite symptom resolution.22 Endoscopic
indices evolved from the Baron score,23 initially developed for rigid proctoscopy in
ambulatory patients with mild to moderate disease, which rated vascular pattern,
mucosal bleeding, and friability. Subsequent endoscopic indices of increasing
complexity incorporated the presence of ulcers, mucopus, granularity, and appear-
ance of light scattering, in addition to bleeding and friability. Such modifications
were intended to improve the capture of disease activity, but they invariably increased
the subjectivity of the scoring system. Table 1 summarizes commonly used endo-
scopic indices for UC, none of which have been validated with the exception of the
UCEIS.31 Nonetheless, there is no agreed threshold for defining either mucosal healing
or endoscopic remission, whichmakes it almost impossible to compare mucosal heal-
ing rates between studies.33
Space does not allow a review of all indices, so this article focuses on the Mayo
Clinic endoscopy subscore, because this is commonly used in clinical trials, and the
UCEIS, which has been validated.
The Mayo Clinic endoscopy subscore has 4 components, with a maximum total
score of 3 (Table 2).26 There is overlap in the features of the different levels of this
endoscopic index, which causes high interobserver variation. The most troublesome
component of this index is friability, as this is subjective and leads to inconsistent re-
sults.34 This inconsistency has lead to an adaptation of the index to remove friability
from level 1.35
The value of this index lies with its widespread use in clinical trials. In trials of inflix-
imab and adalimumab, mucosal healing was defined as a Mayo subscore of 0 or 1 or a
decrease from the baseline subscores of 2 or 3. In Active Ulcerative Colitis Trials, pa-
tients with a posttreatment Mayo score of grade 1 were no more likely to undergo a
colectomy than those with a score of 0.36
The UCEIS (Table 3) was developed because of wide interobserver variation in
endoscopic assessment of disease activity.31 There was only 76% agreement for se-
vere and 27% agreement for normal endoscopic mucosal appearances between 10
experienced investigators and a central reader. Thirty different investigators then rated
25/60 different videos for 10 descriptors and assessed overall severity on a 0 to 100
visual analog scale. Kappa statistics tested interobserver and intraobserver variability
for each descriptor. Different models to predict the overall assessment of severity as
judged by a visual analog scale were developed using general linear mixed regression.
The final model incorporated just 3 descriptors, each with precise definitions. A third
validation phase used another 25 different investigators from North America and
Europe, who assessed in a randomly selected subset of 28/60 videos, including
Table 1
Endoscopic disease activity indicesa for ulcerative colitis
Indexa Validated Variables Strengths Weaknesses
Truelove and Witts
Endoscopy Index21
No Granularity, hyperemia Precedence (first reported index), but
no other merit
No description of endoscopic lesions,
so interobserver variability is high
Baron Index23 No Bleeding, vascular pattern, friability Easy to use Ulcerations not included in score, no
definition of mucosal healing
Powell-Tuck Index24 No Bleeding Easy to use Ulceration not included, no definition
of mucosal healing
Sutherland Index25 No Friability, bleeding, exudation Easy touse;overlap indescriptive terms
used for different levels of activity
Subjective, no definition of mucosal
healing
Mayo Clinic Index:
endoscopic
subscore26
No Vascular pattern, erythema, friability,
erosions and ulcerations, bleeding
Easy to use, commonly used in clinical
trials; overlap in descriptive terms
used for different levels of activity
No validated definition of mucosal
healing
The term minimal or slight friability is
subjective and leads to inconsistent
results
Rachmilewitz Index27 No Granulation, mucosal damage,
vascular pattern, vulnerability of
mucosa (bleeding)
None reported Complex and subjective descriptive
terms
Modified Baron
Index28
No Vascular pattern, granularity,
friability, bleeding, ulceration
Easy to use No validated definition of mucosal
healing
Endoscopic Activity
Index29
No Size of ulcers (4 levels), depth of ulcers
(4 levels), redness (3 levels),
Bleeding (4 levels), mucosal edema
(4 levels), mucosal exudate (3 levels)
Closely correlated with clinical
activity. Comparable to other
indices. Useful in severe disease
Matts Index30 No Granularity, bleeding, edema,
ulceration
Easy to use
Ulcerative Colitis
Endoscopic
Index or Severity31
Preliminary32 Vascular pattern (3 levels), bleeding
(4 levels), ulceration (4 levels)
Easy to use
Independent of clinical symptoms,
accounts for 88% of variation
between observers
Sensitivity to change, and mucosal
healing remain undefined
a The word index is best used for an instrument designed to assess activity and score for the level of activity assigned by the index.31
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Table 2
Mayo endoscopic score
Score Disease Activity Endoscopic Features (Descriptors)
0 Normal or inactive None
1 Mild Erythema, decreased vascular pattern, mild friabilitya
2 Moderate Marked erythema, absent vascular pattern, friability, erosions
3 Severe Spontaneous bleeding, ulceration
a Endoscopic assessment in the mesalamine MMX trials removed friability from level 1 (see text).
Adapted from Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid ther-
apy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med
1987;317:1625–9; with permission.
Walsh et al3722 duplicated videos to assess test-retest reliability. Intraobserver kappa values were
0.82, 0.72, and 0.78 for vascular pattern, bleeding, and erosion and ulcer descriptors,
and interobserver kappa values were 0.83, 0.56, and 0.77, respectively. The correla-
tion coefficient (r2) between UCEIS and overall severity evaluation was 0.94 (P<.0001),
meaning that it accounted for 88% (0.942) of the variation between observers in the
overall assessment of endoscopic activity.32
The term friability invariably needs explanation. The UCEIS dispensed with the term
mucosal friability, because the model including friability as a descriptor did notTable 3
The Ulcerative Colitis Endoscopic Index of Severity
Descriptor
(Score Most
Severe Lesions)
Likert Scale
Anchor Points Definition
Vascular pattern Normal (0) Normal vascular pattern with arborization of
capillaries clearly defined, or with blurring or
patchy loss of capillary margins
Patchy obliteration (1) Patchy obliteration of vascular pattern
Obliterated (2) Complete obliteration of vascular pattern
Bleeding None (0) No visible blood
Mucosal (1) Some spots or streaks of coagulated blood on the
surface of the mucosa ahead of the scope, which
can be washed away
Luminal mild (2) Some free liquid blood in the lumen
Luminal moderate
or severe (3)
Frank blood in the lumen ahead of endoscope or
visible oozing from mucosa after washing
intraluminal blood, or visible oozing from a
hemorrhagic mucosa
Erosions
and ulcers
None (0) Normal mucosa, no visible erosions or ulcers
Erosions (1) Tiny (5 mm) defects in the mucosa, of a white or
yellow color with a flat edge
Superficial ulcer (2) Larger (>5 mm) defects in the mucosa, which are
discrete fibrin-covered ulcers when compared
with erosions, but remain superficial
Deep ulcer (3) Deeper excavated defects in the mucosa, with a
slightly raised edge
Copyright Warner Chilcott Pharmaceuticals, although the index is freely available for use by
investigators.
Adapted from Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a system-
atic review. Gut 2012;61:1619–35.
Mucosal Healing As a Target of Therapy 373perform significantly better than one including bleeding. In practical terms, the most
severely affected part of the mucosa is scored. There are, however, still limitations;
thresholds for remission and mild, moderate, and severe disease have yet to be set.
The extent to which full colonoscopy may influence the score compared with the flex-
ible sigmoidoscopy on which it was based, has only started to be evaluated.37 Knowl-
edge of symptoms does not materially influence the score, and a comparison with the
Mayo Clinic endoscopy subscore shows that the UCEIS is less subject to variation by
a central reader.38 Nevertheless, the UCEIS is simple enough to use in clinical practice
and should achieve its goal of reducing variation in endoscopic assessment of activity
between observers. Clinicians are beginning to use the UCEIS in clinical practice, and
a preliminary study in patients admitted with acute severe colitis shows that a score of
7 or 8 (out of 8) on admission predicted an inadequate response to intravenous ste-
roids and the need for rescue therapy with cyclosporine or infliximab.39 The UCEIS
is now being used in clinical trials of UC that are in progress.
Crohn’s Disease
There are validated endoscopic indices for the assessment of Crohn’s disease activity
(Table 4). The CDEIS is the standard, whereas the SES-CD is a simplified version. The
Rutgeerts Postoperative Endoscopic Index is used for estimating the risk of recur-
rence after ileocolic resection for Crohn’s disease.
The CDEIS40 is a prospectively developed instrument constructed to detect
changes in disease activity and examines 4 endoscopic variables (deep ulceration, su-
perficial ulceration, length of ulcerated mucosa, and length of diseased mucosa) in
each of the following locations: rectum, sigmoid and left colon, transverse colon,
and right colon and ileum (Table 5). The total score is then divided by the numberTable 4
Endoscopic indices for Crohn’s disease
Index Validated Variables Strengths Weaknesses
Crohn’s Disease
Endoscopic
Index of Severity
(CDEIS)40
Yes Superficial and
deep ulceration,
ulcerated and
nonulcerated
stenosis, surface
area of ulcerated
and disease
segments
Standard,
reproducible,
gold standard
Complex, need
experience/
training, difficult
for beginners and
daily routine, no
validated
definition of
mucosal healing
Simple Endoscopic
Score for
Crohn’s Disease
(SES-CD)41
Yes Ulcer size, ulcerated
surface, affected
surface, presence
of stenosis
Simplified index;
performance
correlates with
CDEIS
Validated against
CDEIS in only one
study, less
frequently used
than CDEIS, no
validated
definition of
mucosal healing
Rutgeerts
Postoperative
Endoscopic
Index42
No Aphthous
ulcerations,
inflammation,
ulcers, nodules,
narrowing
Standard for
evaluating
postoperative
recurrence,
validated levels
for predicting
relapse
Only for use after
ileocolic resection
Table 5
Example of the CDEIS scoring form
Rectum
Sigmoid &
Left Colon
Transverse
Colon
Right
Colon Ileum Total
Deep ulcerations (12 present,
0 absent)
0 12 0 12 N/A 24 Total 1
Superficial ulceration
(6 present, 0 absent)
6 6 6 6 N/A 24 Total 2
Surface involved by the
disease (per 10 cm)a
5.6 4.9 3.4 5.6 N/A 19.5 Total 3
Ulcerated surface (per 10 cm)a 0.7 0.5 0.9 0.4 N/A 22 Total 4
Total 1 1 Total 2 1 Total 3 1 Total 4 89.5 Total A
Number (n) of segments totally or partially examined (1–5) 4 n
Total A divided by n 22.4 Total B
Quote 3 if ulcerated stenosis anywhere, 0 if not 3 C
Quote 3 if nonulcerated stenosis anywhere, 0 if not 0 D
Total B 1 C 1 D 25.4 CDEIS
a Analog scales to be converted to numeric values.
Adapted fromMary JY, Modigliani R. Development and validation of an endoscopic index of the
severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes The´rapeutiques des
Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983–9; with permission.
Walsh et al374of locations explored (1–5). An additional 3 points is given if an ulcerated stenosis is
present, and a further 3 points if a nonulcerated stenosis is present. CDEIS scores
range from 0 to 44.
 Deep ulcerations: score 0 if absent or 12 if present
 Superficial ulcerations: score 0 if absent or 6 if present
 Length of ulcerated mucosa (0–10 cm): score 0 to 10 according to length in
centimeters
 Length of diseased mucosa (0–10 cm): score 0 to 10 according to length in
centimeters
Although CDEIS is the standard index and is reproducible, it is also complex. It re-
quires training and experience, especially for estimating ulcerated or diseasedmucosal
surfaces and distinguishing between superficial and deep ulceration. It is cumbersome
to use in clinical practice. The CDEIS has appropriate sensitivity tomeasure changes in
the mucosal appearance. Endoscopic remission (minor or no lesions) is defined as a
CDEIS score less than or equal to 6 or less than or equal to 7, and complete endoscopic
remission (mucosal healing, ie, no lesions at all or scarred lesions only) is defined as a
CDEIS score less than or equal to 3 or less than or equal to 4. An endoscopic response
is a decrease from baseline CDEIS score of at least 4 or 5 points. The CDEIS has been
used in trials of corticosteroids, thiopurines, and TNF antagonists.
In the MUSIC (Endoscopic Mucosal Improvement in Patients With Active Crohn’s
Disease Treated With Certolizumab Pegol) study of certolizumab pegol in Crohn’s dis-
ease, maintenance of improvement between weeks 10 and 54, based on individual
patient data, was found in 70% of those who responded (decline in CDEIS >5) and
those with complete remission (CDEIS<3), and in more than 40% of those with remis-
sion (CDEIS<6).43
The SES-CD (Table 6) correlates well with the CDEIS, with a correlation coefficient
r5 0.920 and excellent interobserver reliability (k coefficients 0.791–1.000). This score
Table 6
Simple Endoscopic Score for Crohn’s Disease
Variable 0 1 2 3
Size of
ulcers (cm)
None Aphthous ulcers
(diameter
0.1–0.5 cm)
Large ulcers
(diameter 0.5–2 cm)
Very large ulcers
(diameter >2 cm)
Ulcerated
surface (%)
None <10 10–30 >30
Affected
surface (%)
Unaffected
segment
<50 50–75 >75
Presence of
narrowings
None Single, can be passed Multiple, can be
passed
Cannot be passed
Total SES-CD: sum of the values of the 4 variables for the 5 bowel segments. Values are given to
each variable and for every examined bowel segment.
Adapted from DapernoM, D’Haens G, Van Assche G, et al. Development and validation of a new,
simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc
2004;60:505–12; with permission.
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ment for Crohn’s disease, one that by contrast would be less complex than the CDEIS.
Selected endoscopic parameters (ulcer size, ulcerated and affected surfaces, steno-
sis) were scored from 0 to 3, whereby SES-CD5 0 equates to absence of ulcers.41 No
cutoff values have been determined for the SES-CD, and there is no definition of
mucosal healing.
The Rutgeerts Postoperative Endoscopic Index (Table 7) determines the severity of
endoscopic disease recurrence at the anastomosis and in the neoterminal ileum after
ileocolic resection.42,44 The severity of endoscopic recurrence predicts clinical recur-
rence, so it has gained popularity.42 In the year after ileocolic resection, patients with a
Rutgeerts score of 0 or 1 have a low risk of clinical recurrence (20% at 3 years follow-
up) compared with those patients who have a score of grade 3 or 4 (92% at 3 years
follow-up). Level 2 is associated with an intermediate risk of clinical recurrence, but
the definition of grade 2 is more subjective and is exposed to variability.
This index has also been incorporated into a randomized clinical trial. In the Post
Operative Crohn’s Endoscopic Recurrence study, it was shown that treating accord-
ing to the risk of recurrence with a 6-month postoperative colonoscopy and treatmentTable 7
Rutgeerts Postoperative Endoscopic Index
Distal Ileum
Grade 0 Nil
Grade 1 5 Aphthous ulcers
Grade 2 >5 Aphthous ulcers with normal intervening mucosa, or skip areas of larger
lesions or lesions confined to the ileocolic anastomosis (ie, <1 cm in length)
Grade 3 Diffuse aphthous ulceration with diffusely inflamed mucosa
Grade 4 Diffuse inflammation with large ulcers, nodules, and/or narrowing
An endoscopic scoring system for postoperative disease recurrence in Crohn’s disease. The original
paper uses the term grade rather than level, and as with other tables, the descriptions are precisely
those used in the original paper.
Adapted from Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative
course of Crohn’s disease. Gastroenterology 1990;99:956–63; with permission.
Walsh et al376step up for those who had a Rutgeerts score i2, is significantly superior to drug ther-
apy alone in preventing postoperative recurrence.45
SUMMARY
The colonoscopic assessment of mucosal healing has proved increasingly important
in the management of both UC and Crohn’s disease. All clinicians should strive for this
goal. There is evidence for a decrease in corticosteroid use, decreased hospitalization,
an increase in sustained remission, and a decrease in the need for surgery. Further
advancements with surrogate noninvasive markers for mucosal healing may help to
overcome existing limitations and need for colonoscopy. Multiple endoscopic indices
exist for UC; however, the only validated index is the UCEIS, and its use in both clinical
practice and clinical trials is encouraged. The CDEIS and the SES-CD are both vali-
dated for Crohn’s disease. The Rutgeerts Postoperative Endoscopic Index is useful
for the prediction of postoperative recurrence in those patients who have had an ileo-
colic resection.
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